SCHEMBL5258047

SCHEMBL5258047

Cn1c(C(=O)N[C@H]2CCCC[C@H]2C(=O)O)cc2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.54
▸ MCL1 Q07820 1/20 0.52
▸ MEN1 O00255 1/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ CNR2 P34972 1/20 0.47
▸ PHGDH O43175 1/20 0.46
▸ CCKAR P32238 1/20 0.46
▸ CCKBR P32239 1/20 0.46
▸ GHSR Q92847 2/20 0.46
▸ KCNH2 Q12809 1/20 0.46
▸ KDM4E B2RXH2 3/20 0.45
▸ HSD17B10 Q99714 3/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ HPGD P15428 1/20 0.45
▸ CGAS Q8N884 1/20 0.44
▸ POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8248425 1.00 CHRNA7 (0.54) CHRNA7MCL1MEN1NPC1RAB9A
SCHEMBL6750613 1.00 CHRNA7 (0.54) CHRNA7MCL1MEN1NPC1RAB9A
SCHEMBL6754251 0.99 CHRNA7 (0.53) CHRNA7MCL1MEN1NPC1RAB9A
SCHEMBL8252421 0.91 CHRNA7 (0.52) CHRNA7MCL1MEN1NPC1RAB9A
SCHEMBL14193441 0.90 CHRNA7 (0.51) CHRNA7MCL1MEN1NPC1RAB9A
SCHEMBL4823902 0.87 CHRNA7 (0.47) CHRNA7MCL1MEN1NPC1RAB9A
SCHEMBL4825296 0.87 CHRNA7 (0.48) CHRNA7MCL1MEN1NPC1RAB9A
SCHEMBL4826808 0.86 CHRNA7 (0.48) CHRNA7MCL1MEN1NPC1RAB9A
SCHEMBL14565626 0.86 TAS1R3 (0.51) CHRNA7MCL1MEN1KMT2ACNR2
SCHEMBL8251025 0.85 CNR2 (0.50) CHRNA7MCL1MEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7358373-B2 Cathepsin K inhibitors ROCHE PALO ALTO LLC (US) 2008-04-15 — — US disclosed
US-7358373-B2 Cathepsin K inhibitors ROCHE PALO ALTO LLC (US) 2008-04-15 — — US disclosed
EP-1453801-B1 SUBSTITUTED 2-AMINO-CYCLOALKANECARBOXAMIDES AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 — — EP disclosed
EP-1453801-B1 SUBSTITUTED 2-AMINO-CYCLOALKANECARBOXAMIDES AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 — — EP disclosed
US-20070032484-A1 Cathepsin K inhibitors ROCHE PALO ALTO LLC 2007-02-08 — — US disclosed
US-20070032484-A1 Cathepsin K inhibitors ROCHE PALO ALTO LLC 2007-02-08 — — US disclosed
US-6759428-B2 SUCH AS N-((1,2)-2-(((CYANO(CYCLOPROPYL)METHYL)AMINO)CARBONYL) CYCLOHEXYL)-1H-INDOLE-2-CARBOXAMIDE; CATHEPSIN K INHIBITORS ROCHE PALO ALTO LLC 2004-07-06 — — US disclosed
US-6747053-B2 Heteroaryl nitriles ROCHE PALO ALTO LLC 2004-06-08 — — US disclosed
US-20040077646-A1 Indole nitriles ROCHE PALO ALTO LLC 2004-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032484-A1 Cathepsin K inhibitors CTSK, CTSS, CTSF CHRNA7 3660/4885MCL1 921/4885MEN1 770/4885
US-20040077646-A1 Indole nitriles TPH1, IDO1, NAT1 CHRNA7 1619/4885MCL1 870/4885MEN1 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback